Immunoprecise Beneish M Score

IPA -  USA Stock  

USD 4.14  0.15  3.50%

This module uses fundamental data of Immunoprecise Antibodies to approximate the value of its Beneish M Score. Immunoprecise Antibodies M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please see Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis.
  
Refresh
Immunoprecise Antibodies Total Debt is projected to increase significantly based on the last few years of reporting. The past year's Total Debt was at 3.98 Million. The current year Debt Current is expected to grow to about 910.8 K, whereas Debt Non Current is forecasted to decline to about 2.3 M. Immunoprecise Antibodies Current Ratio is projected to increase based on the last few years of reporting. The past year's Current Ratio was at 9.25. The current year Tangible Assets Book Value per Share is expected to grow to 4.00, whereas Book Value per Share is forecasted to decline to 3.25.
At this time, it appears that Immunoprecise Antibodies is an unlikely manipulator. The earnings manipulation may begin if Immunoprecise Antibodies' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Immunoprecise Antibodies executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Immunoprecise Antibodies' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.48
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables1.03Focus
Asset Quality-0.05Focus
Expense Coverage1.02Focus
Gross Margin Strengs0.97Focus
Accruals Factor1.02Focus
Depreciation Resistance0.94Focus
Net Sales Growth0.93Focus
Financial Leverage Condition1.25Focus

Immunoprecise Antibodies Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Immunoprecise Antibodies' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues19.1 M20.6 M
Significantly Down
Increasing
Slightly volatile
Selling General and Administrative Expense8.7 M9.2 M
Notably Down
Increasing
Slightly volatile
Depreciation Amortization and Accretion4.7 M4.7 M
Slightly Up
Increasing
Slightly volatile
Total Assets64.2 M77 M
Fairly Down
Increasing
Slightly volatile
Investments129 K127.7 K
Fairly Up
Increasing
Slightly volatile
Investments Non Current129 K127.7 K
Fairly Up
Increasing
Slightly volatile
Property Plant and Equipment Net4.1 M4.6 M
Fairly Down
Increasing
Slightly volatile
Trade and Non Trade ReceivablesM4.2 M
Sufficiently Down
Increasing
Slightly volatile
Total Liabilities9.3 MM
Sufficiently Up
Decreasing
Stable
Current Assets60.6 M56.2 M
Significantly Up
Increasing
Slightly volatile
Assets Non Current16.7 M16.3 M
Fairly Up
Decreasing
Slightly volatile
Current Liabilities5.9 M5.5 M
Notably Up
Decreasing
Slightly volatile
Liabilities Non Current4.6 M4.6 M
Slightly Up
Increasing
Slightly volatile
Total Debt4.2 MM
Notably Up
Increasing
Slightly volatile
Debt Current910.8 K887.4 K
Fairly Up
Decreasing
Slightly volatile
Debt Non Current2.3 M2.8 M
Significantly Down
Increasing
Slightly volatile
Gross Margin0.720.74
Fairly Down
Increasing
Slightly volatile

Immunoprecise Antibodies Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Immunoprecise Antibodies' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Immunoprecise Antibodies in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Immunoprecise Antibodies' degree of accounting gimmicks and manipulations.

About Immunoprecise Antibodies Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Operating Expenses

19.3 Million

Share
Immunoprecise Antibodies Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 21.23 Million

About Immunoprecise Antibodies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Immunoprecise Antibodies Investors Sentiment

The influence of Immunoprecise Antibodies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunoprecise. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Immunoprecise Antibodies Implied Volatility

    
  304.15  
Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunoprecise Antibodies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunoprecise Antibodies' short interest history, or implied volatility extrapolated from Immunoprecise Antibodies options trading.

Current Sentiment - IPA

Immunoprecise Antibodies Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunoprecise Antibodies. What is your judgment towards investing in Immunoprecise Antibodies? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
101.5 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.